Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Label indication Myfortic is an antimetabolite immunosuppressant indicated for prophylaxis of organ rejection in adult patients receiving kidney transplants and in pediatric patients at least 5 years of age and older who are at least 6 months post kidney transplant. ( 1.1 ) Use in combination with cyclosporine and corticosteroids.
Also known as Enteric Coated Mycophenolic Acid (MPA), Enteric-coated mycophenolate sodium, Enteric-coated mycophenolate sodium (EC-MPS), MPA, Cellcept, Mycophenolic Acid (MPA), Mycophenolate sodium, Enteric coated mycophenolate sodium (Myfortic®)
Myfortic · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Myfortic | DRUG | - |
Inclusion Criteria: * Males and females aged 18 to 75 years. * Recipients of first, heart-beating cadaveric, living unrelated or living related non-HLA identical donor kidney transplant, treated with Simulect® and Neoral® as primary immunosuppression. Exclusion Criteria: * Second or subsequent ki...
Myfortic is used in kidney transplantation. It is a small molecule therapy studied in patients receiving a kidney transplant, and it belongs to the nephrology therapeutic area. Its clinical development has focused on this transplant population rather than on other conditions.
Myfortic is developed by Novartis AG, which trades under the ticker NVS. Novartis is the company associated with the drug's clinical program in kidney transplantation.
Myfortic is in Phase 3 development for kidney transplantation. The Phase 3 program includes one completed trial, and no trials are currently listed as active. Myfortic is an investigational therapy in this development stage rather than a product with a stated approval in the information available.
Myfortic has been studied in the Phase 3 Freedom Study, registered as NCT00101738, titled Myfortic in Kidney Transplant Patients. That trial is completed, enrolled 342 participants, and was conducted across the United States, Argentina, Australia, Brazil, Canada, Germany, Italy, Malaysia, New Zealand, Singapore, Spain, Taiwan, and the United Kingdom.
Yes. Myfortic and Myfortic® refer to the same drug. The registered trademark form Myfortic® is simply the branded spelling of the name, so searches for either version point to the same kidney transplantation therapy developed by Novartis AG.